Covaxin Uses, Dosage, Side Effects and more
Covaxin is a vaccine candidate created by the Indian Council of Medical Research (ICMR). The candidate, a whole virion inactivated SARS-CoV-2 vaccine, was developed from a well-known SARS-CoV-2 strain and a vero cell platform (CCL-81) with adjuncts of either aluminum hydroxide gel (Algel) or a novel TLR7/8 agonist adsorbed gel. The components of the vaccine include CovaxinA, CovaxinB, and CovaxinC. Animal studies in mice, rats, and rabbits reported Covaxin immunogenicity at two separate antigen concentrations with both types of adjuvants. The formulation with the TLR7/8 adjuvant specifically induced significant Th1 biased antibody responses and increased SARS-CoV-2 lymphocyte responses. Thus, as of July 2020, Covaxin is in Phase 1/2 clinical trials assessing safety and immunogenicity in humans (NCT04471519).
| Attribute | Details |
|---|---|
| Trade Name | Covaxin |
| Generic | BBV152 |
| BBV152 Other Names | BBV-152, Covaxin, Whole-Virion Inactivated SARS-CoV-2 Vaccine |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
